Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report)'s stock price rose 0.5% on Wednesday . The stock traded as high as $5.85 and last traded at $5.64. Approximately 440,868 shares were traded during trading, a decline of 84% from the average daily volume of 2,818,590 shares. The stock had previously closed at $5.61.
Analyst Ratings Changes
SLDB has been the subject of several recent analyst reports. HC Wainwright increased their target price on Solid Biosciences from $16.00 to $20.00 and gave the company a "buy" rating in a research note on Monday. Citizens Jmp upgraded Solid Biosciences to a "strong-buy" rating in a research note on Tuesday, December 10th. Truist Financial assumed coverage on Solid Biosciences in a research note on Wednesday, January 8th. They set a "buy" rating and a $16.00 target price for the company. Chardan Capital reiterated a "buy" rating and issued a $16.00 price objective on shares of Solid Biosciences in a research report on Friday, March 7th. Finally, JMP Securities assumed coverage on Solid Biosciences in a research report on Tuesday, December 10th. They issued an "outperform" rating and a $15.00 price objective for the company. Nine research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $15.70.
Check Out Our Latest Stock Analysis on SLDB
Solid Biosciences Trading Down 1.0 %
The stock has a fifty day moving average price of $4.18 and a 200-day moving average price of $5.47. The firm has a market capitalization of $394.44 million, a price-to-earnings ratio of -1.67 and a beta of 1.98.
Hedge Funds Weigh In On Solid Biosciences
A number of hedge funds have recently modified their holdings of SLDB. JPMorgan Chase & Co. raised its holdings in shares of Solid Biosciences by 9,393.8% in the 4th quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company's stock worth $3,824,000 after buying an additional 945,863 shares in the last quarter. Redmile Group LLC acquired a new position in shares of Solid Biosciences in the 4th quarter worth approximately $2,461,000. Point72 Asset Management L.P. raised its holdings in shares of Solid Biosciences by 292.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 443,010 shares of the company's stock worth $3,088,000 after buying an additional 330,234 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Solid Biosciences by 270.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 264,069 shares of the company's stock valued at $1,056,000 after purchasing an additional 192,714 shares in the last quarter. Finally, Trexquant Investment LP raised its position in Solid Biosciences by 256.9% in the 4th quarter. Trexquant Investment LP now owns 194,281 shares of the company's stock valued at $777,000 after purchasing an additional 139,851 shares during the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.
Solid Biosciences Company Profile
(
Get Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Featured Articles
Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
